The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
Jon C. Ogg
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment...
Chris Lange
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Chris Lange
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental Petroleum, Spark Therapeutics and Target.
Jon C. Ogg
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
Lee Jackson
The top analyst upgrades, downgrades and other research calls from Wednesday include Anadarko, Apple, Charter Communications, FireEye, First Solar and Frontier Communications.
Jon C. Ogg
Wednesday's top analyst upgrades, downgrades and initiations include Alphabet, Apple, Duke Energy, Kellogg, NVIDIA and Wells Fargo.
Lee Jackson
The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel and Valeant Pharmaceuticals.
Jon C. Ogg
Merrill Lynch brings another company to the forefront that it considers a buy. Ironwood Pharmaceuticals is viewed favorably by the brokerage firm, with nearly 30% upside.
Chris Lange
Source: Jon OggOne of the biggest complaints for years about Wall St. research was that no firm ever said when to sell. Back in the halcyon days of the late 1980s, and through the 1990s, many stock...
Lee Jackson
These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Thursday, September 4, 2014.
Jon C. Ogg
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Lee Jackson
Source: ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in...
Lee Jackson
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Jon C. Ogg